A Synopsis of Biomarkers in Glioblastoma: Past and Present

• Published in: Current issues in molecular biology 2024-07, Vol.46 (7), p.6903-6939
• Main Authors: Tataranu, Ligia Gabriela, Turliuc, Serban, Rizea, Radu Eugen, Dricu, Anica, Alexandru, Oana, Staicu, Georgiana-Adeline, Kamel, Amira
• Format: Article
• Language: English
• Subjects: biomarkers; biomolecular; glioblastoma; immunotherapy; neurosurgery
• ISSN: 1467-3045; 1467-3037; 1467-3045
• DOI: 10.3390/cimb46070412

Accounting for 48% of malignant brain tumors in adults, glioblastoma has been of great interest in the last decades, especially in the biomolecular and neurosurgical fields, due to its incurable nature and notable neurological morbidity. The major advancements in neurosurgical technologies have positively influenced the extent of safe tumoral resection, while the latest progress in the biomolecular field of GBM has uncovered new potential therapeutical targets. Although GBM currently has no curative therapy, recent progress has been made in the management of this disease, both from surgical and molecular perspectives. The main current therapeutic approach is multimodal and consists of neurosurgical intervention, radiotherapy, and chemotherapy, mostly with temozolomide. Although most patients will develop treatment resistance and tumor recurrence after surgical removal, biomolecular advancements regarding GBM have contributed to a better understanding of this pathology and its therapeutic management. Over the past few decades, specific biomarkers have been discovered that have helped predict prognosis and treatment responses and contributed to improvements in survival rates.